IPC Founding President Alan Menter and IPC Councilor Ulrich Mrowietz discuss the new guidance on psoriasis care from the National Psoriasis Foundation COVID-19 Task Force.
They join an esteemed group of IPC psoriasis experts working to better patient care We are pleased to introduce our newest IPC Councilors, including for the first time, dermatologists from Bangladesh and Guatemala. Councilors are selected based on overall reputation in the dermatology community, involvement in psoriasis research, and demonstrated interest in psoriasis care and treatment. Meet our councilors.
Declaración del IPC sobre COVID y psoriasis La pandemia de SARS-CoV-2 continúa siendo una preocupación sanitaria de gravedad a nivel global. Desde que el Consejo Internacional de Psoriasis (IPC) publicó su declaración sobre COVID-19 el 11 de marzo, el coronavirus continúa propagándose rápidamente y actualmente constituye un peligro sanitario preponderante en todos los países de ingresos económicos altos, medios y bajos.
IPC fellow Dr. Romina Contreras talks with Dr. Alba Català about her study on skin manifestations of COVID-19 and how this research contributes to our growing understanding of the novel coronavirus.
The registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects patients with psoriasis.
In moderate to severe psoriasis, there has been a long-lasting tradition to define outcome as a relative change from baseline PASI, with the classical PASI 75 being more recently replaced by PASI 90 or 100. However, this concept is dated, mainly due to the impressive development of anti-interleukin therapies and an increasing interest in real-world evidence.
Torres writes that several comorbidities known to be associated with psoriasis, such as cardiovascular disease, hypertension, diabetes or obesity, have been identified as risk factors for severe COVID-19 outcomes.
Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage.
Having cared for psoriasis patients via teledermatology for more than 10 years prior to the pandemic, I recognize the benefits and limitations of teledermatology for managing psoriasis. I would like to share a few practice pearls.
Searching for signals of increased risk of infection in specific subgroups is vitally important, especially when confronted with a severe threat to health, like the worldwide spread of the SARS-CoV-2 virus.
Commentary from IPC Councilor Mark Lebwohl, MD, on a case series in NEJM on COVID-19 in immune-mediated inflammatory diseases.
Dr. Lluís Puig provides his comments on a recent publication on the classification of the cutaneous manifestations of COVID‐19.
The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics